Who Paid My Doc
Thomas Schermoly
Colon & Rectal Surgery Mooresville, IN Doctor of Osteopathy
NPI 1356979892 CMS profile 11917343
1215 Hadley Rd Ste 201, Mooresville, IN 46158
General payments
$124
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Thomas Schermoly of Mooresville, IN is reported in the CMS Open Payments database as having received $124 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 8th percentile of Colon & Rectal Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $124 | 2 |
Beside peers
- Thomas Schermoly
- Colon & Rectal Surgery median
- Middle half of Colon & Rectal Surgery
- National median
In program year 2025, general payments to Thomas Schermoly were reported at $124. Among 1,481 Colon & Rectal Surgery profiles paid that year, the median was $317 and the middle half received between $109 and $1,248.
Show as a table
| Year | Thomas Schermoly | Colon & Rectal Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $443 | $125–$2,179 | $163 |
| 2020 | $0 | $167 | $53–$931 | $114 |
| 2021 | $0 | $207 | $72–$1,272 | $132 |
| 2022 | $0 | $341 | $111–$1,587 | $149 |
| 2023 | $0 | $322 | $115–$1,420 | $160 |
| 2024 | $0 | $328 | $112–$1,354 | $164 |
| 2025 | $124 | $317 | $109–$1,248 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
79
Drug cost
$435
Branded share of claims
20.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ondansetron Odt Ondansetron | Brand | 16 | $216 | |
| Oxycodone Hcl | Generic | 47 | $181 | |
| Tramadol Hcl | Generic | 16 | $38 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Colon & Rectal Surgery in Indiana
Shekar Narayanan
Colon & Rectal Surgery · Indianapolis, IN
Imran Ahmad
Colon & Rectal Surgery · Munster, IN
Edward Delle Donne
Colon & Rectal Surgery · South Bend, IN
Joshua Wallet
Colon & Rectal Surgery · Fort Wayne, IN
Santiago Arruffat
Colon & Rectal Surgery · Evansville, IN
William Oh
Colon & Rectal Surgery · Mooresville, IN
Related records
Colon & Rectal Surgery in Indiana
Practitioners in the same specialty and state, ranked by reported value.
All Colon & Rectal Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Indiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.